IU receives $2M gift supporting lung, pancreatic cancer research

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

Ovarian cancer cells may quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better, a study published by Mayo Clinic researchers suggests.

February 20, 2026

Vol.52 No.07

Drugs & Targets

FDA approves pancreatic cancer device

FDA approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields, to the abdomen.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives.

February 13, 2026

Vol.52 No.06

Clinical Trials & Tribulations

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

January 16, 2026

Vol.52 No.02

By Kevin King

Clinical Trials & Tribulations

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Lung cancer remains the leading cause of cancer death in the United States, largely because it is most often diagnosed at an advanced stage.

Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors need closer monitoring because their cancer is more likely to recur.

December 19, 2025

Vol.51 No.46

IU receives $2M gift supporting lung, pancreatic cancer research

YOU MAY BE INTERESTED IN

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

FDA approves pancreatic cancer device

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence

Renew today!

Subscriber content

Never miss an issue!

Login